Survodutide Phase 2 trial (NCT04667377)
A Phase II, Randomized, Double Blind, Parallel Group,46 Weeks Dose-finding Study of BI 456906 Administered Once Weekly Subcutaneously Compared With Placebo in Patients With Obesity or Overweight
At a glance
- Phase
- Phase 2
- Status
- Completed
- Enrolment
- 387
- actual
- Start
- 8 Mar 2021 (actual)
- Primary completion
- 15 Sep 2022 (actual)
- Sponsor
- Boehringer Ingelheim
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| 0.6 mg BI 456906 | Experimental | Drug: BI 456906 | Not stated |
| Placebo group | Placebo comparator | Drug: Placebo | Not stated |
| 2.4 mg BI456906 | Experimental | Drug: BI 456906 | Not stated |
| 3.6 mg BI 456906 | Experimental | Drug: BI 456906 | Not stated |
| 4.8 mg BI 456906 | Experimental | Drug: BI 456906 | Not stated |
Primary endpoint
| Measure | Time frame |
|---|---|
| Percentage Change in Body Weight From Baseline to Week 46 | Baseline, Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46. |
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Weight Loss of ≥ 5% of Baseline Weight at Week 46 | At baseline and at Week 46. |
| Weight Loss of ≥ 10% of Baseline Weight at Week 46 | At baseline and at Week 46. |
| Weight Loss of ≥ 15% of Baseline Weight at Week 46 | At baseline and at Week 46. |
| Absolute Change in Body Weight From Baseline to Week 46 | Baseline, Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46. |
| Absolute Change in Waist Circumference From Baseline to Week 46 | Baseline, Week 6, 12, 18, 24, 32, 40, and 46. |
| Absolute Change in Systolic Blood Pressure From Baseline to Week 46 | Baseline, Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46. |
| Absolute Change in Diastolic Blood Pressure From Baseline to Week 46 | Baseline, Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46. |
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Results
Results are posted on the registry. Open the ClinicalTrials.gov record for NCT04667377.
Survodutide dose-finding in obesity without diabetes
Participants were randomised 1:1:1:1:1 to survodutide 0.6, 2.4, 3.6 or 4.8 mg or placebo weekly for 46 weeks: 20 weeks of escalation and 26 of maintenance.[2]
Planned-treatment weight changes at week 46 were -6.2% (0.6 mg), -12.5% (2.4 mg), -13.2% (3.6 mg) and -14.9% (4.8 mg), against -2.8% on placebo.[2]
Adverse events occurred in 91% of survodutide recipients and 75% of placebo recipients, mainly gastrointestinal in 75% and 42% respectively.[2]
Sources
- 1A Phase II, Randomized, Double Blind, Parallel Group,46 Weeks Dose-finding Study of BI 456906 Administered Once Weekly Subcutaneously Compared With Placebo in Patients With Obesity or OverweightClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
- 2Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.The lancet. Diabetes & endocrinology · 2024PMID 38330987Accessed 2 Oct 2026
Found an error? Report a correction.